Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
生物納米基因(納斯達克：bngo-Get Rating)和Telesis Bio(納斯達克：DNAY-GET Rating)都是小盤醫療公司，但哪隻股票更好？我們將根據這兩家公司的股息、收益、盈利能力、機構所有權、風險、估值和分析師的建議來比較它們的實力。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and target prices for Bionano Genomics and Telesis Bio, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Bionano基因組公司和Telesis Bio公司最近的評級和目標價格細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bionano Genomics | 0 | 0 | 2 | 0 | 3.00 |
| Telesis Bio | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 生物納米基因組學 | 0 | 0 | 2 | 0 | 3.00 |
| Telesis Bio | 0 | 0 | 2 | 0 | 3.00 |
Bionano Genomics presently has a consensus target price of $7.75, indicating a potential upside of 409.87%. Telesis Bio has a consensus target price of $5.00, indicating a potential upside of 303.23%. Given Bionano Genomics' higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Telesis Bio.
生物納米基因組公司目前的共識目標價為7.75美元，這表明潛在的上漲幅度為409.87%。Telesis Bio的共識目標價為5美元，表明潛在上漲303.23%。考慮到Bionano基因組學更有可能的上行空間，研究分析師顯然認為Bionano基因組學比Telesis Bio更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Bionano Genomics | -451.42% | -38.48% | -34.11% |
| Telesis Bio | -251.04% | -73.65% | -51.19% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 生物納米基因組學 | -451.42% | -38.48% | -34.11% |
| Telesis Bio | -251.04% | -73.65% | -51.19% |
Insider and Institutional Ownership
內部人與機構持股
26.9% of Bionano Genomics shares are held by institutional investors. Comparatively, 42.7% of Telesis Bio shares are held by institutional investors. 1.2% of Bionano Genomics shares are held by company insiders. Comparatively, 30.2% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Bionano基因公司26.9%的股份由機構投資者持有。相比之下，Telesis Bio 42.7%的股份由機構投資者持有。Bionano基因公司1.2%的股份由公司內部人士持有。相比之下，Telesis Bio 30.2%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一隻股票的長期表現將好於大盤。
Valuation and Earnings
估值和收益
This table compares Bionano Genomics and Telesis Bio's gross revenue, earnings per share (EPS) and valuation.
該表格比較了Bionano Genonics和Telesis Bio的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bionano Genomics | $17.98 million | 25.10 | -$72.43 million | ($0.41) | -3.71 |
| Telesis Bio | $11.04 million | 3.32 | -$38.96 million | ($1.80) | -0.69 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 生物納米基因組學 | 1,798萬美元 | 25.10 | -7243萬美元 | ($0.41) | -3.71 |
| Telesis Bio | 1104萬美元 | 3.32 | -3,896萬元 | ($1.80) | -0.69 |
Telesis Bio has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Telesis Bio的收入較低，但收益高於Bionano基因組公司。生物納米基因組公司的市盈率低於Telesis Bio，這表明它目前是兩隻股票中更負擔得起的一隻。
Volatility & Risk
波動性與風險
Bionano Genomics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
BioNano Genonics的貝塔係數為2.15，表明其股價的波動性比標準普爾500指數高出115%。相比之下，Telesis Bio的貝塔係數為1.38，這表明其股價的波動性比標準普爾500指數高38%。
Summary
摘要
Bionano Genomics beats Telesis Bio on 7 of the 12 factors compared between the two stocks.
在兩隻股票之間的12個因素中，生物納米基因組學在7個因素上擊敗了Telesis Bio。
About Bionano Genomics
關於Bionano基因組學
(Get Rating)
(獲取評級)
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
生物納米基因組公司提供基因組分析軟件解決方案。它提供了用於通過光學基因組圖譜進行結構變異分析的樣本到結果的解決方案，用於基因組分析和了解遺傳變異和功能；SAHERR儀器，一個單分子成像儀；SETRUR芯片，一個包裝用於DNA線性化的納米通道陣列的消耗品；以及Bionano製備試劑盒和DNA標記試劑盒，它提供了提取和標記超高分子量的試劑和協議。該公司還提供Skerr和Bionano計算機服務器；以及NxClinic，該公司提供一個系統，用於分析和解釋微陣列的基因組變異，以及細胞遺傳學和分子遺傳學的下一代測序數據。此外，它還提供檢測和實驗室服務，包括FirstStepDx plus，一個染色體微陣列，用於確定自閉症譜系障礙、發育遲緩和智力殘疾的潛在遺傳原因；脆性X綜合徵(FXS)測試服務；NextStepDx plus，一個外顯子組測序測試，以確定與兒童發育障礙有關的基因變異；EpiPanelDx plus，為經歷過癲癇、嬰兒痙攣、腦病或發熱性癲癇的患者提供基因測試小組；PGx測試，在11個基因中確定60多個等位基因。該公司成立於2003年，總部設在加利福尼亞州聖地亞哥。
About Telesis Bio
關於Telesis Bio
(Get Rating)
(獲取評級)
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Codex DNA公司是一家合成生物學公司，主要向世界各地的製藥和學術實驗室製造和銷售合成生物學儀器、試劑和相關產品及相關服務。它的解決方案包括BioXp系統，它使研究人員能夠從數字DNA序列過渡到終端就緒的合成DNA；BioXp門户網站，它提供了直觀的指導工作流程和設計工具，用於構建新的DNA序列並將其組裝成選擇的載體；BioXp試劑盒，其中包含用於特定合成生物學工作流程應用的構建塊和試劑，包括其Gibson Assembly品牌試劑；基於雲的腳本；Benchtop試劑，包含使用BioXp系統生成的產品在桌面上進行特定合成生物學工作流程所需的所有試劑；Biofoundry服務，使客户能夠訂購和接收BioXp系統終端就緒型產品，如基因、克隆、無細胞擴增DNA和變異庫；以及短寡聚連接組裝酶DNA合成。它還為政府機構、合同研究組織和合成生物學公司提供服務。該公司前身為SGI-DNA，Inc.，並於2020年3月更名為Codex DNA，Inc.。Codex DNA，Inc.成立於2011年，總部設在加利福尼亞州聖地亞哥。
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Bionano基因組學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bionano Genonics和相關公司的最新新聞和分析師評級的每日簡要摘要。